FOLD

NEUTRALM&A

Amicus Therapeutics, Inc.

2026-03-13

Price

$14.37

+0.00%

Score6.5Priority

Signals5/8 DNA2/13 Act · 1/4 Risk

SentimentNEUTRALScore: 7

Volume0.8xvs 20d avg

Analysis

Amicus Therapeutics (FOLD) is exhibiting classic merger arbitrage price action following the recent shareholder approval of its acquisition by BioMarin Pharmaceutical. The exceptionally low realized volatility of 2.1% and the QUIET_STORM technical signal directly reflect the stock's price anchoring to the final deal terms. In a severe RISK_OFF macro regime driven by geopolitical stagflation, FOLD's +3.2% relative strength is not organic market leadership, but rather the result of its M&A-insulated profile acting as a safe haven.

Fired Signals

ALPHA MALEQUIET STORMGOLDEN CROSSBOLLINGER SQUEEZEPERFECT STACKSELLER FATIGUEBARGAIN HUNTERWEAK FINISH

Key Takeaways

Actionable Thesis: FOLD is a pure M&A arbitrage play anchored near its $14.38 acquisition price, offering a zero-beta safe harbor against current geopolitical market volatility.
Key Risk: Regulatory pushback or unforeseen deal-breaking conditions could cause the stock to plummet to its pre-deal baseline.
What to Watch: Monitor final regulatory approvals and the official closing date of the BioMarin merger.

← Back to 2026-03-13 View Full FOLD History →Yahoo Finance &nearr;